West Pharma, Venus Remedies expand partnership to launch NovaGuard SA Pro Safety System in India
Advertisement
Hyderabad: West Pharmaceutical Services, Inc. (West), a global leader in innovative solutions for injectable drug administration, recently announced its partnership with domestic Indian pharma company Venus Remedies Ltd. whose brand Cloti-Xa has made its introduction in the growing low molecular weight heparin market and has adopted the NovaGuard SA Pro safety system, a single-use accessory for prefilled ISO standard 1mL long staked-needle syringes.
The NovaGuard SA Pro safety system is a product with innovative safety features that help protect healthcare workers and patients from accidental needlestick injuries. Several biopharmaceutical manufacturers have commented that this product delivers a compelling total cost of ownership in that it prevents pre-activation, offers a lower syringe snap-in force and a lower activation force for end-user comfort, and mitigates the practice of recapping which helps to provide tamper evidence to customers.
Alagu Subramaniam, Managing Director, West India said, "We at West are committed to improving patients' health and are excited to extend our partnership with Venus Remedies on this new product launch, by delivering unique and innovative packaging products and services. This partnership helps us bring the benefits of our innovative NovaGuard SA Pro safety system to the Indian market, and we will continue to extend the range of our innovative solutions to local customers and patients worldwide."
The NovaGuard SA Pro safety system:
. Has been designed to prevent pre-activation during handling;
. Includes tamper-resistant functionality;
. Provides transparency for drug inspection and labeling;
. Has an ease-of-use assembly;
Speaking on the partnership, Saransh Chaudhary, Chief Executive Officer Venus Medicine Research Centre said, "We are delighted to enter into a partnership with West to produce Cloti-Xa PFS with the innovative NovaGuard® SA Pro safety system in India. Cloti-Xa is expected to provide patients and healthcare providers with an additional advantage of safety from accidental needlestick injuries, which could lead to the spread of infections like HIV and Hepatitis B and C. So far, no other enoxaparin formulation in India seems to offer this additional benefit apart from the innovator brand. Enoxaparin use has increased significantly in ICUs after it has been found useful in reducing hospitalization and mortality in COVID-19 patients. I am positive that it is going to be a high-yielding addition to our portfolio, and we intend to add more such innovative products into our product line."
The NovaGuard SA Pro 1mL safety system has FDA 510k clearance in the U.S. and meets the European 2010/32/EU directive for the prevention of sharps injuries. Designed for both cut and circular syringe flanges, the NovaGuard SA Pro safety system has design features that lock when used and has minimal impact upon syringe filling lines.
The NovaGuard® SA Pro safety system has also won the India Packaging Awards for Excellence in Enhanced User Experience and Excellence in Packaging Design - Shapes and Structures during the UBM InnoPack Pharma Conference's India Packaging Awards ceremony.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.